6-溴-8-氯喹啉 | 16567-13-8

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-溴-8-氯喹啉
• 英文名称: 6-bromo-8-chloroquinoline
• CAS: 16567-13-8
• 化学式: C₉H₅BrClN
• 分子量: 242.502
• InChiKey: BDEUOIMCEVFYET-UHFFFAOYSA-N

物化性质

• 熔点：
  119.5-120 °C
• 沸点：
  327.8±22.0 °C(Predicted)
• 密度：
  1.673±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-8-chloroquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-8-chloroquinoline
CAS number: 16567-13-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H5BrClN
Molecular weight: 242.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	8-chloroquinoline-6-carbaldehyde	916812-11-8	C10H6ClNO	191.617
  ——	8-chloro-6-vinylquinoline	——	C11H8ClN	189.644

反应信息

• 作为反应物：
  描述：

  6-溴-8-氯喹啉 在 manganese(IV) oxide 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium chlorite 、 正丁基锂 、 二乙胺基三氟化硫 、 氨基磺酸 、 sodium acetate 、 臭氧 、 溶剂黄146 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醚 、 乙醇 、 正己烷 、 二氯甲烷 、 水 、 异丙醇 为溶剂， 反应 9.75h， 生成 N-(4-cyanopyridin-2-yl)-6-[difluoro(pyrimidin-5-yl)methyl]quinoline-8-carboxamide
  参考文献：
  名称：

  发现代谢型谷氨酸受体亚型5的6-（嘧啶-5-基甲基）喹啉-8-羧酰胺负变构调节剂。

  摘要：

  基于以前的工作，在我们的mGlu 5负变构调节剂（NAMs）铅系列中将稠合杂环确定为吡啶啉核心的可行替代品，我们设计了一系列新颖的6-（嘧啶-5-基甲基）喹啉-8-羧酰胺mGlu。5个NAM。这些新的喹啉衍生物还含有碳连接基，以取代我们以前发表的化学型通用的二芳基醚氧原子。化合物在基于细胞的功能性mGlu 5分析中进行了评估，并使用了类似的类似物27相对于其他七个mGlu受体，其选择性> 60倍。还在大鼠和人S9肝组分的代谢稳定性测定中研究了所选化合物，并显示了P450和非P450介导的代谢的混合物。

  DOI：

  10.1016/j.bmcl.2018.04.053
• 作为产物：
  描述：

  4-溴-2-氯苯胺 、 烯丙醇 在 dipotassium peroxodisulfate 、 氧气 、 potassium iodide 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 120.0 ℃ 、101.33 kPa 条件下， 反应 12.0h， 以64%的产率得到6-溴-8-氯喹啉
  参考文献：
  名称：

  从苯胺到喹啉：碘化物和银介导的好氧双CH氧化环化-芳构化

  摘要：

  由苯胺等容易获得的原料合成喹啉是一项宝贵而有意义的任务。在本文中，我们传达了苯胺和烯丙醇之间碘化物和银介导的CH / CH氧化环化-芳香化反应。该协议提供了从廉价商品合成喹啉衍生物的直接途径。各种苯胺，甚至杂环苯胺，都是可行的底物，可产生高收率的相应多取代喹啉。

  DOI：

  10.1002/chem.201703218

文献信息

• Enantioselective Three-Component Fluoroalkylarylation of Unactivated Olefins through Nickel-Catalyzed Cross-Electrophile Coupling
  作者：Hai-Yong Tu、Fang Wang、Liping Huo、Yuanbo Li、Shengqing Zhu、Xian Zhao、Huan Li、Feng-Ling Qing、Lingling Chu

  DOI：10.1021/jacs.0c03708

  日期：2020.5.27

  A nickel-catalyzed, enantioselective, three-component fluoroalkylarylation of unactivated alkenes with aryl halides and perfluoroalkyl iodides has been described. This cross-electrophile coupling protocol utilizes a chiral nickel/BiOx system as well as a pendant chelating group to facilitate the challenging three-component, asymmetric difunctionalization of unactivated alkenes, providing direct access

  镍催化、对映选择性、三组分氟烷基芳基化未活化的烯烃与芳基卤化物和全氟烷基碘化物已被描述。这种交叉亲电偶联方案利用手性镍/BiOx 系统以及悬垂的螯合基团来促进未活化烯烃的具有挑战性的三组分不对称双官能化，从而以高效和出色的对映选择性直接获得有价值的手性 β-氟烷基芳基烷烃. 温和的条件允许广泛的底物范围以及良好的官能团耐受性。
• DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES
  申请人：Felicitex Therapeutics, Inc.

  公开号：US20180179199A1

  公开（公告）日：2018-06-28

  The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

  本发明涉及化学式（I）的化合物及其盐、立体异构体、互变异构体或N-氧化物。本发明进一步涉及将这种化合物或盐、立体异构体、互变异构体或N-氧化物用作药物的用途，以及包含该化合物的药物组合物。
• Substituted Bicyclic Heteroaryl Carboxamide Analogs As Mglur5 Negative Allosteric Modulators
  申请人：Vanderbilt University

  公开号：US20150266866A1

  公开（公告）日：2015-09-24

  Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明披露了代谢型谷氨酸受体亚型5（mGluR5）的负向变构调节剂；制备该化合物的合成方法；包含该化合物的制药组合物；以及使用该化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。本摘要旨在作为搜索特定领域的扫描工具，不限制本发明。
• 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE
  申请人：Jiangsu Hengrui Medicine Co. Ltd.

  公开号：EP3569596A1

  公开（公告）日：2019-11-20

  The present invention relates to a 1,2,4-triazine-3-amine derivative, a preparation therefor, and use thereof in medicine. Specifically, the present invention relates to a 1,2,4-triazine-3-amine derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and use thereof as a therapeutic agent, in particular as an A2a receptor antagonist, and use thereof in the preparation of a medicament for treating a condition or disorder that is ameliorated by means of inhibition of the A2a receptor, each substituent in general formula (I) being same as defined in the description.

  本发明涉及一种1,2,4-三嗪-3-胺衍生物、其制备方法及其在医药中的用途。具体地说，本发明涉及通式（I）所代表的1,2,4-三嗪-3-胺衍生物、其制备方法、包含该衍生物的药物组合物及其作为治疗剂的用途，特别是作为A2a受体拮抗剂的用途，以及其在制备用于治疗通过抑制A2a受体而改善的病症或紊乱的药物中的用途，通式（I）中的各取代基与描述中所定义的相同。
• Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases
  申请人：Felicitex Therapeutics, Inc.

  公开号：US10577365B2

  公开（公告）日：2020-03-03

  The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

  本发明涉及式（I）化合物及其盐、立体异构体、同分异构体或 N-氧化物。本发明还涉及这种化合物或其盐、立体异构体、同分异构体或 N-氧化物的药物用途以及包含所述化合物的药物组合物。